# A Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic Melanoma

> **NCT02644967** · PHASE2 · COMPLETED · sponsor: **Idera Pharmaceuticals, Inc.** · enrollment: 53 (actual)

## Conditions studied

- Metastatic Melanoma

## Interventions

- **DRUG:** IMO-2125
- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT02644967
- **Lead sponsor:** Idera Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12
- **Primary completion:** 2020-02
- **Final completion:** 2021-05
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2022-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02644967

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02644967, "A Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic Melanoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02644967. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*